Severi G

No ORCID on file · 10 papers in corpus
2023
Use of menopausal hormone therapy and ovarian cancer risk in a French cohort study.
Journal of the National Cancer Institute ·doi:10.1093/jnci/djad035

BackgroundEpidemiological studies have found that menopausal hormone therapy (MHT) use is associated with an increased ovarian cancer risk. However, whether different MHT types confer the same level of risk is unclear. We estimated the asso…

2022
Colorectal cancer risk following appendectomy: a pooled analysis of three large prospective cohort studies.
Cancer communications (London, England) ·doi:10.1002/cac2.12265
2017
Association Between Telomere Length and Risk of Cancer and Non-Neoplastic Diseases: A Mendelian Randomization Study.
JAMA oncology ·doi:10.1001/jamaoncol.2016.5945

ImportanceThe causal direction and magnitude of the association between telomere length and incidence of cancer and non-neoplastic diseases is uncertain owing to the susceptibility of observational studies to confounding and reverse causati…

2017
Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer.
Nature genetics ·doi:10.1038/ng.3826

To identify common alleles associated with different histotypes of epithelial ovarian cancer (EOC), we pooled data from multiple genome-wide genotyping projects totaling 25,509 EOC cases and 40,941 controls. We identified nine new susceptib…

2016
Acrylamide and Glycidamide Hemoglobin Adducts and Epithelial Ovarian Cancer: A Nested Case-Control Study in Nonsmoking Postmenopausal Women from the EPIC Cohort.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology ·doi:10.1158/1055-9965.epi-15-0822

BackgroundAcrylamide was classified as "probably carcinogenic to humans (group 2A)" by the International Agency for Research on Cancer. Epithelial ovarian cancer (EOC) is the fourth cause of cancer mortality in women. Five epidemiological s…

2016
No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.
Gynecologic Oncology ·doi:10.1016/j.ygyno.2015.04.034

ObjectiveClinical genetic testing is commercially available for rs61764370, an inherited variant residing in a KRAS 3' UTR microRNA binding site, based on suggested associations with increased ovarian and breast cancer risk as well as with …

2015
Vitamin D metabolic pathway genes and pancreatic cancer risk.
PloS one ·doi:10.1371/journal.pone.0117574

Evidence on the association between vitamin D status and pancreatic cancer risk is inconsistent. This inconsistency may be partially attributable to variation in vitamin D regulating genes. We selected 11 vitamin D-related genes (GC, DHCR7,…

2014
Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA.
Human genetics ·doi:10.1007/s00439-013-1383-3

Epithelial ovarian cancer (EOC) is a heterogeneous cancer with both genetic and environmental risk factors. Variants influencing the risk of developing the less-common EOC subtypes have not been fully investigated. We performed a genome-wid…

other 2014
Risk of ovarian cancer and the NF-κB pathway: genetic association with IL1A and TNFSF10
Cancer research ·doi:10.1158/0008-5472.CAN-13-1051

A missense single-nucleotide polymorphism (SNP) in the immune modulatory gene IL1A has been associated with ovarian cancer risk (rs17561). Although the exact mechanism through which this SNP alters risk of ovarian cancer is not clearly unde…

2013
Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer.
Nature communications ·doi:10.1038/ncomms2629

HNF1B is overexpressed in clear cell epithelial ovarian cancer, and we observed epigenetic silencing in serous epithelial ovarian cancer, leading us to hypothesize that variation in this gene differentially associates with epithelial ovaria…